| アブストラクト | INTRODUCTION: The increasing availability of routinely collected healthcare data presents opportunities to generate real-world evidence (RWE) to inform regulatory, clinical, and policy decisions. However, fragmented data sources, heterogeneous data structures, and inconsistent coding systems hinder reliable, large-scale analyses. Federated data networks adopting a common data model, such as the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM), offer a standardised, privacy-preserving approach to addressing these challenges. METHODS: We established a federated data network comprising seven UK-based partners, each maintaining routinely collected healthcare data mapped to the OMOP CDM. A central coordinating centre develops and distributes standardised analytical code for local execution within each partner's secure environment. Only aggregated, non-identifiable results are returned to the coordinating centre, enabling reproducible analyses while preserving data privacy. Partner c followed a three-stage process comprising database description, benchmarking, and comprehensive data characterisation to assess data quality, support study feasibility, and improve understanding of the available data. RESULTS: The network comprises five English National Health Service (NHS) trusts, one primary care data provider, and one Scottish NHS trust. Collectively, the participating databases contain records representing approximately 57.2 million individuals, 1.73 billion drug exposures, and 854 million condition records. The population estimate does not account for potential overlap between data sources. CONCLUSIONS: We established a large-scale UK federated healthcare data network using the OMOP CDM, integrating diverse primary and secondary care data sources within a privacy-preserving analytical framework. The network provides an infrastructure for standardised, reproducible, multi-database observational research and supports the generation of RWE to inform healthcare decision-making. |
| ジャーナル名 | Pharmacoepidemiology and drug safety |
| Pubmed追加日 | 2026/11/14 |
| 投稿者 | Campanile, Cecilia; Knight, Alex E; Junaid, Hiba; Lane, Jennifer C E; Rahman, Usama; Eaton, Ben; Griffin, Xavier L; South, Andy; Cavalcante, Ana; Piatek, Stefan; Briot Ribeyre, Baptiste; Harris, Steve; Howcroft, Timothy; Chandrabalan, Vishnu; Hall, Peter S; Vallet, Maheva; Pasikowska, Marta; Symmers, Nicola; McLean, Colin; Nita, Spyro; Dedman, Daniel; Cuccu, Zara; Theophanous, Stelios; Hall, Geoff; Bolton, Edward; Patel, Shiren; Key, Daniel; Briggs, Lydia; Khadka, Prasiddha; Seymour, David; Rowlands, Elin; Newby, Danielle; Prieto-Alhambra, Daniel; Burn, Edward; Catala, Marti |
| 組織名 | Health Data Sciences, Nuffield Department of Orthopaedics, Rheumatology and;Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.;Health Data Research UK (HDR UK), London, UK.;Barts Bone and Joint Health, Queen Mary University of London, London, UK.;Barts Health NHS Trust, NHS Trust, London, UK.;Barts Life Sciences, London, UK.;University College London Hospitals Biomedical Research Centre, London, UK.;Institute of Health Informatics, University College London, London, UK.;Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.;DataLoch, Edinburgh Cancer Informatics, University of Edinburgh, Edinburgh, UK.;Clinical Practice Research Datalink (CPRD), Medicines and Healthcare Products;Regulatory Agency (MHRA), London, UK.;Leeds Teaching Hospitals NHS Trust, London, UK.;Data Research, Innovation and Virtual Environments (DRIVE), Great Ormond Street;Hospital for Children, London, UK.;Department of Medical Informatics, Erasmus MC University, Rotterdam, the;Netherlands. |
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/43025859/ |